Show simple item record

dc.contributor.authorNorman, JEen_US
dc.contributor.authorMarlow, Nen_US
dc.contributor.authorMessow, C-Men_US
dc.contributor.authorShennan, Aen_US
dc.contributor.authorBennett, PRen_US
dc.contributor.authorThornton, Sen_US
dc.contributor.authorRobson, SCen_US
dc.contributor.authorMcConnachie, Aen_US
dc.contributor.authorPetrou, Sen_US
dc.contributor.authorSebire, NJen_US
dc.contributor.authorLavender, Ten_US
dc.contributor.authorWhyte, Sen_US
dc.contributor.authorNorrie, Jen_US
dc.contributor.authorGrp, OPPTIMUMSen_US
dc.date.accessioned2016-05-19T13:12:03Z
dc.date.available2016-02-23en_US
dc.date.issued2016-05-21en_US
dc.date.submitted2016-04-18T12:19:44.818Z
dc.identifier.issn0140-6736en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/12435
dc.description.sponsorshipEfficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute for Health Research (NIHR) partnership. The EME Programme is funded by the MRC and NIHR, with contributions from the Chief Scientist Office in Scotland and National Institute for Social Care and Research in Wales.en_US
dc.format.extent2106 - 2116en_US
dc.relation.ispartofLANCETen_US
dc.titleVaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trialen_US
dc.typeArticle
dc.rights.holder© Norman et al. Open Access article distributed under the terms of CC BY.
dc.identifier.doi10.1016/S0140-6736(16)00350-0en_US
pubs.author-urlhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000376450800034&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6aen_US
pubs.issue10033en_US
pubs.notesNot knownen_US
pubs.publication-statusPublisheden_US
pubs.volume387en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record